The CCR2 3'UTR functions as a competing endogenous RNA to inhibit breast cancer metastasis

Area of Science:

• Molecular Biology
• Cancer Research
• RNA Biology

Background:

• Competing endogenous RNAs (ceRNAs) co-regulate gene expression by sponging microRNAs.
• CCR2 protein is linked to cancer progression, but CCR2 mRNA levels correlate with better breast cancer survival.
• The non-coding function of CCR2 mRNA in cancer remains largely unexplored.

Purpose of the Study:

• To investigate the non-coding function of CCR2 mRNA in breast cancer metastasis.
• To elucidate the molecular mechanisms underlying CCR2 mRNA's role in suppressing metastasis.

Main Methods:

• In vitro and in vivo metastasis assays using breast cancer cell lines (MDA-MB-231, MCF-7).
• Analysis of the CCR2 3' untranslated region (UTR) as a competing endogenous RNA (ceRNA).
• Investigation of the RhoA-ROCK1-MLC-F-actin pathway and its regulation by CCR2 3'UTR and STARD13.

Main Results:

• The CCR2 3'UTR significantly inhibited breast cancer cell metastasis in vitro and in vivo.
• CCR2 3'UTR functions as a ceRNA for STARD13, modulating its expression independently of protein coding.
• CCR2 3'UTR suppressed the RhoA-ROCK1 pathway by inhibiting STARD13, leading to decreased MLC2 phosphorylation and F-actin formation.

Conclusions:

• The CCR2 3'UTR acts as a metastasis suppressor in breast cancer.
• This suppressive function is mediated by the ceRNA activity of CCR2 3'UTR for STARD13.
• The CCR2 3'UTR inhibits breast cancer metastasis via the STARD13-RhoA-ROCK1-MLC-F-actin signaling axis.